Corneal endothelial dystrophy - Pipeline Insight, 2021
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Corneal endothelial dystrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal endothelial dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Corneal endothelial dystrophy: Overview
The term “corneal endothelial dystrophy” refers to a group of diseases that are characterized by a slowly progressive endogenous degeneration of corneal endothelium and are at least in part due to genetic predisposition. The corneal endothelial dystrophies are congenital hereditary endothelial dystrophy 1 (CHED1), congenital hereditary endothelial dystrophy 2 (CHED2), posterior polymorphous corneal dystrophy (PPCD) and Fuchs endothelial corneal dystrophy (FECD). In all cases, degeneration of corneal endothelium ultimately leads to severely impaired vision or blindness, but the molecular pathologies remain largely unknown. Recent efforts have shed more light on the molecular mechanisms of these diseases, and the latest genetic findings enforce the idea of a gradual continuum between endothelial dystrophies. Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane.
'Corneal endothelial dystrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Corneal endothelial dystrophy pipeline landscape is provided which includes the disease overview and Corneal endothelial dystrophy treatment guidelines. The assessment part of the report embraces, in depth Corneal endothelial dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Corneal endothelial dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Corneal endothelial dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Corneal endothelial dystrophy Emerging Drugs
Further product details are provided in the report……..
Corneal endothelial dystrophy: Therapeutic Assessment
This segment of the report provides insights about the different Corneal endothelial dystrophy drugs segregated based on following parameters that define the scope of the report, such as:
Corneal endothelial dystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Corneal endothelial dystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Corneal endothelial dystrophy drugs.
Corneal endothelial dystrophy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Corneal endothelial dystrophy - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Corneal endothelial dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Corneal endothelial dystrophy: Overview
The term “corneal endothelial dystrophy” refers to a group of diseases that are characterized by a slowly progressive endogenous degeneration of corneal endothelium and are at least in part due to genetic predisposition. The corneal endothelial dystrophies are congenital hereditary endothelial dystrophy 1 (CHED1), congenital hereditary endothelial dystrophy 2 (CHED2), posterior polymorphous corneal dystrophy (PPCD) and Fuchs endothelial corneal dystrophy (FECD). In all cases, degeneration of corneal endothelium ultimately leads to severely impaired vision or blindness, but the molecular pathologies remain largely unknown. Recent efforts have shed more light on the molecular mechanisms of these diseases, and the latest genetic findings enforce the idea of a gradual continuum between endothelial dystrophies. Fuchs endothelial corneal dystrophy (FECD) is the most common corneal dystrophy and frequently results in vision loss. Hallmarks of the disease include loss of corneal endothelial cells and formation of excrescences of Descemet’s membrane.
'Corneal endothelial dystrophy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Corneal endothelial dystrophy pipeline landscape is provided which includes the disease overview and Corneal endothelial dystrophy treatment guidelines. The assessment part of the report embraces, in depth Corneal endothelial dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Corneal endothelial dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Corneal endothelial dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Corneal endothelial dystrophy.
This segment of the Corneal endothelial dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Corneal endothelial dystrophy Emerging Drugs
- TTHX1114: Trefoil Therapeutics
- Netarsudil mesylate: Aerie Pharmaceuticals
Further product details are provided in the report……..
Corneal endothelial dystrophy: Therapeutic Assessment
This segment of the report provides insights about the different Corneal endothelial dystrophy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Corneal endothelial dystrophy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- intravitreal
- Subretinal
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Corneal endothelial dystrophy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Corneal endothelial dystrophy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Corneal endothelial dystrophy drugs.
Corneal endothelial dystrophy Report Insights
- Corneal endothelial dystrophy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Corneal endothelial dystrophy drugs?
- How many Corneal endothelial dystrophy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Corneal endothelial dystrophy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Corneal endothelial dystrophy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Corneal endothelial dystrophy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Trefoil Therapeutics
- Aerie Pharmaceuticals
- Kowa Research Institute, Inc.
- Emmecell
- Surrozen
- TTHX1114
- Netarsudil mesylate
- K-321
- EO2002
Introduction
Executive Summary
Corneal endothelial dystrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase II/III)
Comparative Analysis
Netarsudil: Price Vision Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TTHX1114: Trefoil Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EO2002: Emmecell
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Corneal endothelial dystrophy Key Companies
Corneal endothelial dystrophy Key Products
Corneal endothelial dystrophy- Unmet Needs
Corneal endothelial dystrophy- Market Drivers and Barriers
Corneal endothelial dystrophy- Future Perspectives and Conclusion
Corneal endothelial dystrophy Analyst Views
Corneal endothelial dystrophy Key Companies
Appendix
Executive Summary
Corneal endothelial dystrophy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase II/III)
Comparative Analysis
Netarsudil: Price Vision Group
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TTHX1114: Trefoil Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EO2002: Emmecell
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Corneal endothelial dystrophy Key Companies
Corneal endothelial dystrophy Key Products
Corneal endothelial dystrophy- Unmet Needs
Corneal endothelial dystrophy- Market Drivers and Barriers
Corneal endothelial dystrophy- Future Perspectives and Conclusion
Corneal endothelial dystrophy Analyst Views
Corneal endothelial dystrophy Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Corneal endothelial dystrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Corneal endothelial dystrophy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Corneal endothelial dystrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Corneal endothelial dystrophy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
